Patient description: A 45-year-old woman was referred to the emergency department with abdominal pain lasting about 4 days accompanied by nausea and 2 episodes of vomiting. The pain is localized to the epigastric region and radiates to the right upper quadrant. The pain is worsening after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and two C/sections. She has 2 children, and she is menopausal. She doesn't smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones and biliary sludge. The largest gallstone is 0.7cm. Surgery consultation recommends elective cholecystectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-66.0,  Hepatic and Hepatobiliary Disorders Males and females ≥18 years of age and less than 66 years old Patients with gastrointestinal symptoms (fatigue, abdominal pain/discomfort, early satiety, fullness discomfort after meal, nausea/vomiting, belching/abdominal distension, at least one rated as "Moderate Problem" or higher severity at screening visit) in acute and chronic liver diseases receiving conventional treatment for the underlying pathology Before entering the study, patients will be advised to stop alcohol intake and must agree not to consume alcohol and undergo alcohol withdrawal program, diet control, and exercise program The patient is able and willing to undertake all study required procedures and has the ability to take oral medications Patients with nonalcoholic fatty liver disease (NAFLD) diagnosed by ultrasound examination in absence of severe fibrosis as per Investigator's judgment Diagnosis of acute or chronic viral hepatitis as manifested by a combination of the following symptoms: jaundice (acute viral hepatitis), dark-colored urine (acute viral hepatitis), light-colored stools (acute viral hepatitis), pruritus, pruritic red hives, fever, nausea, vomiting, anorexia, aversion to smoking and right upper abdominal discomfort, pain or feeling of pressure, with abnormal alanine aminotransferase (ALT) (approximately 1.5 x upper limit of normal [ULN]) Patient has given written informed consent Fertile patients must agree to use an acceptable method of contraception to avoid pregnancy for the duration of the study Total abstinence from sexual intercourse (minimum one complete menstrual cycle prior to study drug administration) Vasectomized partner of female subjects  Patients <18 years of age and >66 years old Female patient of childbearing potential without negative pregnancy test Breastfeeding woman Hypersensitivity to phosphatidylcholine or any substance of the product Patient is known to be human immunodeficiency virus (HIV) positive Congenital lack of α-1 antitrypsin Gastroesophageal Reflux Disease (GERD) Autoimmune hepatitis Fulminant hepatitis Severe steatohepatitis: transaminases level is beyond 5 times upper normal range